Company Overview

Your present location:Home >> Shareholders Introduction

China Otsuka Pharmaceutical Co., Ltd.

China Otsuka Pharmaceutical Co., Ltd., the first Sino-Japanese joint venture and the first joint venture pharmaceutical companies in China, was co-invested by China Pharmaceutical Group, Tianjin Pharmaceutical Group Co., Ltd. and Japan's Otsuka Group in 1981.


The trademark "COP" was rated as China's well-known trademark, and nowadays, COP has become the integrated pharmaceutical manufacturer owning various products such as infusion, plastic ampoule injection, eye drops and nutrition infusion with its own brand. Currently, it has owned offices in 23 provinces and cities, and its marketing networks have covered 31 provinces and cities nationwide. COP has two affiliated companies — Guangdong Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. Dalian. In 2013, the consolidated revenue of COP was 860,000,000 yuan.

Chinese shareholder: China Pharmaceutical Group Corporation
China Pharmaceutical Group, the medicine health industry group with biggest scale, best-equipped industrial chain and strongest overall strength in China, is managed by SASAC directly and mainly engages in distribution, retail, R&D and production of products related to health such as prevention & treatment, diagnostic & care, etc. It owns 11 wholly owned or holding subsidiaries and 6 listed companies including Sinopharm Group Co., Ltd, Sinopharm shares, China National Accord Medicines Corporation Ltd., Tiantan Biological Products Co., Ltd, Modern Pharmaceutical Co., Ltd and China Traditional Chinese Medicine Co. Limited. From 2003 to 2013, the Group's operating income increased by an annual average of 31%, gross profit increased by an annual average of 42%, total assets increased by an annual average of 32% and in 2013, its operating revenue was in excess of 200 billion yuan. China Pharmaceutical Group was the first Chinese pharmaceutical company to rank among the Fortune Global 500 in 2012. Besides, it ranked 357th among the Fortune Global 500 and top 8 among global pharmaceutical companies in July, 2014.


Japanese foreign shareholders: Japanese Otsuka Pharmaceutical Co., Ltd.
Otsuka Group was founded in 1921 and produced inorganic compounds initially. Nowadays, Otsuka Group has developed into a multinational enterprise group owning more than 140 companies. Otsuka Holdings Co., Ltd. was established in 2008 and became the listed company in Japan in 2010.
Otsuka Pharmaceutical Co., Ltd., one of the core companies of Otsuka Group, was founded in 1964. Its core businesses include pharmaceutical business and nutraceutical business. Pharmaceutical business focuses on central nervous system, cardio cerebral vascular system, digestive system, respiratory system, dermatology and ophthalmology and engages in development, production and sale of medical drugs. Because of its advanced technology, Otsuka Pharmaceutical infusion products are well known to world and have a market share of about 50% in Japan.




About Us | Digital Map | Contact Us | Legal Notices | Backstage Management
All rights reserved:Guangdong Otsuka Pharmaceutical Co., Ltd. | "Internet drug information service qualification certificate" :( Guangdong) ─ non-operating ─2009─0035  GuangDong ICP No. 09154721 | Technical
Add: High-tech Industrial Park, Ronggui Street, Shunde District, Foshan City, Guangdong Province, China | Tel:0757-28305861 | Fax:0757-28305862